Rivus Pharmaceuticals Presents Preclinical Non-Human Primate Data on Oral GLP-1 Candidate RV-8451 at ADA Meeting
Rivus Pharmaceuticals announced preclinical results for its oral GLP-1 receptor agonist RV-8451 at the American Diabetes Association's 86th Scientific Sessions on June 5, 2026.
Rivus Pharmaceuticals, Inc. announced preclinical data for RV-8451, a novel, muscle-preserving, oral GLP-1 receptor agonist in development for obesity treatment, on June 05, 2026. m.
CT on June 05, 2026 at the American Diabetes Association's 86th Scientific Sessions in New Orleans, LA. The sessions run June 5-8, 2026. Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health.
In the NHP studies, RV-8451 produced significant fat-specific weight loss while preserving lean mass and showed no gastrointestinal adverse events. In a head-to-head NHP study, RV-8451 resulted in greater fat loss versus orforglipron while preserving lean mass. , Chief Scientific Officer of Rivus Pharmaceuticals.
"In two independent studies in obese NHPs, RV-8451 produced robust, fat-selective weight loss while preserving lean mass," Khan said. " IND-enabling studies for RV-8451 are advancing, with IND submission for RV-8451 in obesity targeted for Q1 2027.
